XORTX Therapeutics Inc (XRTX.V) expected to post a loss of 33 cents a share - Earnings Preview
I'm PortAI, I can summarize articles.
XORTX Therapeutics Inc (XRTX.V) is anticipated to report a loss of 33 cents per share for the period ending December 31, 2024, with results expected on March 31. The sole analyst rating is a "buy," and the median 12-month price target is $14.00, significantly higher than the last closing price of $0.96. The mean earnings estimate has remained unchanged over the past three months.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments